TY - JOUR
T1 - Genetic risk score in diabetes associated with chronic pancreatitis versus type 2 diabetes mellitus
AU - Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
AU - Goodarzi, Mark O.
AU - Nagpal, Tanvi
AU - Greer, Phil
AU - Cui, Jinrui
AU - Chen, Yii Der I.
AU - Guo, Xiuqing
AU - Pankow, James S.
AU - Rotter, Jerome I.
AU - Alkaade, Samer
AU - Amann, Stephen T.
AU - Baillie, John
AU - Banks, Peter A.
AU - Brand, Randall E.
AU - Conwell, Darwin L.
AU - Cote, Gregory A.
AU - Forsmark, Christopher E.
AU - Gardner, Timothy B.
AU - Gelrud, Andres
AU - Guda, Nalini
AU - LaRusch, Jessica
AU - Lewis, Michele D.
AU - Money, Mary E.
AU - Muniraj, Thiruvengadam
AU - Papachristou, Georgios I.
AU - Romagnuolo, Joseph
AU - Sandhu, Bimaljit S.
AU - Sherman, Stuart
AU - Singh, Vikesh K.
AU - Wilcox, C. Mel
AU - Pandol, Stephen J.
AU - Park, Walter G.
AU - Andersen, Dana K.
AU - Bellin, Melena D.
AU - Hart, Phil A.
AU - Yadav, Dhiraj
AU - Whitcomb, David C.
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019
Y1 - 2019
N2 - INTRODUCTION: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM (T2DM) remains uncertain. Addressing this question is needed for development of specific measures to manage CP-DM. We approached this question from a unique standpoint, hypothesizing that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and T2DM.METHODS: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of Atherosclerosis, all of European origin.RESULTS: The mean GRS was identical between 321 subjects with CP-DM and 423 subjects with T2DM (66.53 vs 66.42, P = 0.95), and the GRS of both diabetic groups was significantly higher than that of nondiabetic controls (n = 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of the GRS to distinguish between CP-DM and T2DM.DISCUSSION: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be a subtype of T2DM, a notion that should be tested in future, large prospective studies.
AB - INTRODUCTION: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM (T2DM) remains uncertain. Addressing this question is needed for development of specific measures to manage CP-DM. We approached this question from a unique standpoint, hypothesizing that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and T2DM.METHODS: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of Atherosclerosis, all of European origin.RESULTS: The mean GRS was identical between 321 subjects with CP-DM and 423 subjects with T2DM (66.53 vs 66.42, P = 0.95), and the GRS of both diabetic groups was significantly higher than that of nondiabetic controls (n = 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of the GRS to distinguish between CP-DM and T2DM.DISCUSSION: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be a subtype of T2DM, a notion that should be tested in future, large prospective studies.
UR - http://www.scopus.com/inward/record.url?scp=85070669728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070669728&partnerID=8YFLogxK
U2 - 10.14309/ctg.0000000000000057
DO - 10.14309/ctg.0000000000000057
M3 - Article
C2 - 31232720
AN - SCOPUS:85070669728
SN - 2155-384X
VL - 10
JO - Clinical and translational gastroenterology
JF - Clinical and translational gastroenterology
IS - 7
M1 - e-00057
ER -